Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNYTE: RP1 alone and with nivolumab in solid tumors
2024-511728-15-00Phase 2Completed
- Sponsor
- Replimune Group, Inc.
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of vusolimogene oderparepvec and nivolumab in Nonhematologic neoplasms, melanoma, cutaneous melanoma (CM) and 4 more, sponsored by Replimune Group, Inc. Started Sep 2024; status: completed.
02
Drugs
vusolimogene oderparepvecnivolumab
03
Conditions
Nonhematologic neoplasmsmelanomacutaneous melanoma (CM)non-melanoma skin cancer (NMSC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511728-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511728-15-00.